Oncolytics Biotech (ONCY) Prices 8M Shares at $4 (Halted)
Tweet Send to a Friend
Up)
Oncolytics Biotech, Inc. (NASDAQ: ONCY) announced today the pricing of an underwritten public offering of 8.0 million common shares, at a public offering price of US$4.00 per common share.
Piper Jaffray & Co. and Wedbush PacGrow Life Sciences are acting as joint book-running managers for the offering in the U.S. and Paradigm Capital Inc. is acting as co-manager in the U.S. and book-running manager in Canada.
NOTE: Share halted
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Piper Jaffray & Co. and Wedbush PacGrow Life Sciences are acting as joint book-running managers for the offering in the U.S. and Paradigm Capital Inc. is acting as co-manager in the U.S. and book-running manager in Canada.
NOTE: Share halted
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Chile regulators stopped build, imposed sanctions on Barrick Gold (ABX)
- Silver Wheaton (SLW) Comments on Pascua-Lama; 'Remain Confident' in Barrick (ABX)
- Oncolytics Biotech (ONCY) REOLYSIN w/ REO 020 Met Primary Endpoint in Phase 2
Create E-mail Alert Related Categories
Equity Offerings, Trading HaltsRelated Entities
Piper Jaffray
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
